BMJ Open (Dec 2020)

Effects of low-dose hydrocortisone and hydrocortisone plus fludrocortisone in adults with septic shock: a protocol for a systematic review and meta-analysis of individual participant data

  • Yaseen Arabi,
  • Sylvie Chevret,
  • Laurent Billot,
  • Anthony Gordon,
  • Didier Keh,
  • Romain Pirracchio,
  • Balasubramanian Venkatesh,
  • Djillali Annane,
  • Andre Waschka,
  • Jeremy Cohen,
  • Simon Finfer,
  • Naomi Hammond,
  • John Myburgh,
  • Anthony Delaney,
  • Pierre Edouard Bollaert,
  • Josef Briegel,
  • Ling Liu,
  • G Umberto,
  • Liliana Mirea,
  • L Charles,
  • Nejla Tilouche,
  • Surat Tongyoo,
  • Ruiqiang Zheng

DOI
https://doi.org/10.1136/bmjopen-2020-040931
Journal volume & issue
Vol. 10, no. 12

Abstract

Read online

Introduction The benefits and risks of low-dose hydrocortisone in patients with septic shock have been investigated in numerous randomised controlled trials and trial-level meta-analyses. Yet, the routine use of this treatment remains controversial. To overcome the limitations of previous meta-analyses inherent to the use of aggregate data, we will perform an individual patient data meta-analysis (IPDMA) on the effect of hydrocortisone with or without fludrocortisone compared with placebo or usual care on 90-day mortality and other outcomes in patients with septic shock.Methods and analysis To assess the benefits and risks of hydrocortisone, with or without fludrocortisone for adults with septic shock, we will search major electronic databases from inception to September 2020 (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and Latin American Caribbean Health Sciences Literature), complimented by a search for unpublished trials. The primary analysis will compare hydrocortisone with or without fludrocortisone to placebo or no treatment in adult patients with septic shock. Secondary analyses will compare hydrocortisone to placebo (or usual care), hydrocortisone plus fludrocortisone to placebo (or usual care), and hydrocortisone versus hydrocortisone plus fludrocortisone. The primary outcome will be all cause mortality at 90 days. We will conduct both one-stage IPDMA using mixed-effect models and machine learning with targeted maximum likelihood analyses. We will assess the risk of bias related to unshared data and related to the quality of individual trial.Ethics and dissemination This IPDMA will use existing data from completed randomised clinical trials and will comply with the ethical and regulatory requirements regarding data sharing for each of the component trials. The findings of this study will be submitted for publication in a peer-review journal with straightforward policy for open access.PROSPERO registration number CRD42017062198.